SEMAGLUTIDE & TIRZEPATIDE

Over the past few years some new injectable medications have been approved for type 2 Diabetes. Two of these medications have been found to work very well for weight loss.

In June of 2021, the FDA approved Semaglutide for weight loss. In May of 2022, the FDA approved Tirzepatide for type 2 Diabetes. It has been "fast tracked" for weight loss approval. 

They tend to work on the brain to decrease appetite and cravings, on the stomach to slow gastric emptying (eat less and stay satisfied longer), and on the whole body to improve insulin resistance (which may help prevent weight regain).

Early studies show very good weight loss. On average, a weight loss of about 15% of body weight for Semaglutide and about 20% of body weight for Tirzepatide. (for example, a 200 pound person may lose 30-40 lbs.)

Both medications need to be started at a low dose and slowly increased each month depending on patient tolerance and weight loss.

The meds potentially can have some side effects (about 5% of patients may need to stop the medications due to intolerance). Potential side effects include nausea, vomiting, diarrhea, constipation, indigestion or abdominal pain, and burping. Very rarely serious side effects could occur - allergic reactions, pancreatitis, or gallbladder disease. 

If you are interested in further information and want to start the process to utilize injectable medications, please contact the office and watch Dr. Clark's informative webinar. 

 *Costs: $150 for the consultation with Dr. Clark
$299/month for Semaglutide or $399/month for Tirzepatide  (High doses of Tirzepatide will be $499/month)

You may qualify to receive $100 off the first month of medication.